Sign Up Today and Learn More About Ascidian Therapeutics Stock
Invest in or calculate the value of your shares in Ascidian Therapeutics or other pre-IPO companies through EquityZen's platform.
Ascidian Therapeutics Stock (ASTH)
Ascidian Therapeutics is a biotechnology company that focuses on medical and clinical gene therapy.
About Ascidian Therapeutics Stock
Founded
2020
Headquarters
Boston, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Ascidian Therapeutics Press Mentions
Stay in the know about the latest news on Ascidian Therapeutics
Ascidian Therapeutics Announces Formation of Scientific Advisory Board
citybiz • May 07, 2025
Ascidian Therapeutics Announces Formation of Scientific Advisory Board
biospace • May 06, 2025
Ascidian Therapeutics Announces Formation of Scientific Advisory Board
prnewswire • May 06, 2025
Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more
globenewswire • Apr 29, 2025
Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact
endpts • Mar 28, 2025
Ascidian Therapeutics Management
Leadership team at Ascidian Therapeutics
Chief Medical Officer
Jay Barth
President and CEO
Romesh Subramanian
Join now and verify your accreditation status to gain access to:
- Ascidian Therapeutics Current Valuation
- Ascidian Therapeutics Stock Price
- Ascidian Therapeutics Management
- Available deals in Ascidian Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Ascidian Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Ascidian Therapeutics Revenue and Financials
- Ascidian Therapeutics Highlights
- Ascidian Therapeutics Business Model
- Ascidian Therapeutics Risk Factors
- Ascidian Therapeutics Research Report from SACRA Research
Trading Ascidian Therapeutics Stock
How to invest in Ascidian Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Ascidian Therapeutics through EquityZen funds. These investments are made available by existing Ascidian Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Ascidian Therapeutics stock?
Shareholders can sell their Ascidian Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
